You are here

Pulmonary Hypertension Drug Riociguat Submitted for Agency Approval

Walking distance improved in two phase III trials (Feb. 11)

A new drug application (NDA) has been submitted to the FDA seeking approval for riociguat (Bayer), an investigational compound for the treatment of pulmonary arterial hypertension (PAH) and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH.

The submission is supported by data from two global phase III studies of riociguat (the CHEST-1 and PATENT-1 trials). Data from these two studies were presented in October 2012 at CHEST 2012, the annual meeting of the American College of Chest Physicians (ACCP). Both phase III trials of riociguat met their primary endpoints.

In the CHEST-1 study, 261 patients with inoperable CTEPH or with persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) were randomly assigned to treatment with either riociguat or placebo for 16 weeks. In the PATENT-1 study, 445 patients with symptomatic PAH received two different doses of riociguat or placebo over 12 weeks. In both studies, the primary endpoint was improvement in the 6-minute walking distance.

Riociguat (BAY 63-2521) is an investigational oral soluble guanylate cyclase (sGC) stimulator that is being studied in CTEPH and PAH, as well as in other forms of pulmonary hypertension.

Source: Bayer; February 11, 2013.

Recent Headlines

Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial